Mexico NOM-137-SSA1-2025 Medical Device Labeling Update

Mexico has officially published NOM-137-SSA1-2025, replacing the previous NOM-137-SSA1-2008 medical device labeling standard. The updated regulation modernizes labeling requirements for medical devices in Mexico, with stronger focus on traceability, sterile product labeling, safety information, and post-market surveillance alignment.

The new standard also moves Mexico closer to international regulatory practices by incorporating harmonized symbols, clearer import labeling requirements, and broader lifecycle safety expectations. While the NOM is applicable from publication, mandatory compliance becomes effective on May 14, 2027.

Most Important Changes

Why NOM-137-SSA1-2025 Matters

The previous 2008 version focused largely on basic labeling content requirements. The 2025 revision goes significantly further by emphasizing:

• Device traceability

• Risk management

• Lifecycle safety

• Harmonized symbols

• Sterility communication

• Consistency across regulatory documentation

• Electronic and digital labeling support

The regulation also aligns more closely with modern international regulatory principles commonly seen in frameworks such as ISO 13485, IMDRF concepts, and global post-market surveillance expectations.

Key Regulatory Themes in the New Standard

1. Traceability Takes Center Stage

One of the most notable additions is the explicit inclusion of traceability requirements within medical device labeling. The regulation now emphasizes identification elements such as:

• Lot numbers

• Serial numbers

• Manufacturing dates

• Expiration dates

• Device identification controls

The standard also permits electronic support tools such as QR codes, RFID, and barcodes to supplement labeling information.

While Mexico has not formally implemented a UDI system equivalent to the EU MDR or FDA UDI framework, this change strongly suggests future movement toward enhanced device traceability infrastructure.

For manufacturers, this means now is the ideal time to evaluate:

• Label data architecture

• ERP traceability capabilities

• Barcode strategy

• Global labeling harmonization opportunities

2. Greater Use of International Symbols

The updated NOM expands the acceptance and structure around internationally harmonized labeling symbols. Manufacturers may now rely more heavily on standardized symbols, provided risks related to user comprehension are appropriately evaluated.

This shift creates opportunities to:

• Reduce multilingual label congestion

• Harmonize global packaging artwork

• Align Mexican labeling with EU and other international markets

However, companies should expect:

• Artwork redesign activities

• Symbol validation reviews

• Human factors and risk management assessments

Manufacturers using legacy text-heavy labels may need substantial updates to maintain compliance.

3. Enhanced Requirements for Sterile Devices

Sterile devices are expected to experience the greatest regulatory impact under the new NOM.

The standard introduces stronger expectations regarding:

• Sterility status declarations

• Sterilization methods

• Packaging integrity warnings

• Expiration dating

• Storage and handling precautions

• End-of-life considerations

Packaging systems and Instructions for Use (IFUs) will likely require revision to ensure all required sterility information is appropriately communicated.

This is especially significant for:

• Surgical products

• Implantables

• Single-use sterile devices

• Procedure kits

• Sterile IVDs

Manufacturers should anticipate increased scrutiny during:

• Registration reviews

• Import inspections

• Post-market investigations

• Complaint trending activities

4. Stronger Rules for Contra-Labels and Imported Products

The updated regulation clarifies requirements for Mexican counter-labeling (“contra-etiquetas”), which are commonly used for imported devices.

This change could significantly affect:

• Foreign manufacturers

• Importers

• Distributors

• OEM/private label models

• Local relabeling operations

Companies relying heavily on local Mexican relabeling processes should carefully reassess:

• Label ownership responsibilities

• Distributor agreements

• Translation controls

• Artwork approval workflows

• Warehouse relabeling practices

Operationally, this may require tighter coordination between global regulatory, quality, and supply chain teams.

5. Labeling Is Now More Closely Linked to Post-Market Surveillance

Perhaps the most strategic change is the stronger integration between labeling compliance and lifecycle safety management.

The new NOM explicitly connects labeling controls with:

• Risk management

• Complaint handling

• Adverse event reporting

• Device traceability

• Quality management systems

This reflects a global regulatory trend toward treating labeling as a living component of device safety rather than a static market authorization requirement.

Manufacturers should expect COFEPRIS to increasingly evaluate consistency between:

• Registration dossiers

• Commercial labels

• IFUs

• Technical documentation

• PMS systems

• QMS records

Areas Most Likely to Affect Foreign Manufacturers

Label and IFU Updates

Manufacturers will likely need to revise:

• Outer labels

• Instructions for Use

• Sterile barrier labeling

• Safety warnings

• Storage conditions

• Traceability identifiers

• Symbol usage

Greater Documentation Consistency Expectations

Regulators will likely expect tighter alignment across:

• Technical files

• Device master records

• Label claims

• Product specifications

• Clinical evidence

• Registration submissions

Inconsistencies that may have historically gone unnoticed could now attract regulatory attention.

Increased Impact on Importation Operations

Foreign manufacturers using Mexican distributors or importers may face operational changes regarding:

• Counter-labeling

• Packaging controls

• Translation governance

• Artwork approvals

• Relabeling responsibilities

Higher Scrutiny for Sterile Devices

Sterile devices will likely become a focal point for inspections and registration assessments due to enhanced sterility-related labeling requirements.

Expanded PMS Integration

Labeling is increasingly viewed as part of the overall product lifecycle management system, reinforcing the importance of:

• Complaint trending

• CAPA linkage

• Field safety communication

• Traceability readiness

Device Types with Highest Expected Impact

Transition Timeline

According to the published standard:

• Publication Date: May 19, 2026

• Effective Compliance Date: May 14, 2027

• Transition Period: Approximately 360 calendar days

The regulation also includes provisions allowing companies additional time to exhaust existing packaging inventory under certain conditions.

What Manufacturers Should Do Now

To prepare for compliance, companies should begin:

Gap Assessments

Review current Mexican labeling against new NOM-137-SSA1-2025 requirements.

IFU and Artwork Reviews

Evaluate:

• Symbols

• Warnings

• Sterility statements

• Traceability fields

• Spanish-language content

Distributor and Importer Alignment

Clarify ownership of:

• Contra-labeling

• Translation approvals

• Artwork control

• Label release procedures

QMS Integration

Ensure labeling controls align with:

• Risk management

• PMS systems

• Complaint handling

• Change control

• Document management

Sterile Product Risk Review

Conduct targeted reviews for:

• Sterility claims

• Packaging validation

• Shelf-life communication

• Integrity warnings

Final Thoughts

NOM-137-SSA1-2025 represents one of the most significant updates to Mexico’s medical device regulatory framework in years. While many changes align Mexico more closely with international expectations, the operational impact for manufacturers—particularly foreign companies—could be substantial.

Organizations that begin remediation activities early will be better positioned to:

• Avoid supply disruptions

• Reduce relabeling risks

• Maintain registration consistency

• Improve audit readiness

• Strengthen lifecycle compliance

For global manufacturers, this update is more than a labeling change—it is a signal that Mexico continues moving toward a more mature, integrated, and internationally harmonized medical device regulatory environment.

For the official text, please refer to the DOF publication.

Learn more about:

• COFEPRIS Mexico Medical Device Registration